Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC34A1 | Q06495 | 4/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17200646 | 0.95 | MAPT (0.36) | MAPTKDM4EGALR3HTTSMN1; SMN2 | |
| SCHEMBL17200664 | 0.93 | SLC34A1 (0.37) | MAPTKDM4EGALR3HTTSMN1; SMN2 | |
| SCHEMBL170510 | 0.93 | MAPT (0.36) | MAPTKDM4EGALR3HTTSMN1; SMN2 | |
| SCHEMBL17200658 | 0.90 | HSD11B1 (0.36) | MAPTKDM4EGALR3HTTSMN1; SMN2 | |
| SCHEMBL17200645 | 0.90 | MAPT (0.36) | MAPTKDM4EGALR3HTTSMN1; SMN2 | |
| SCHEMBL175788 | 0.90 | MAPT (0.37) | MAPTKDM4EGALR3HTTSMN1; SMN2 | |
| SCHEMBL170832 | 0.88 | SLC34A1 (0.38) | MAPTKDM4EGALR3HTTSMN1; SMN2 | |
| SCHEMBL173411 | 0.87 | SLC34A1 (0.38) | MAPTKDM4EGALR3HTTSMN1; SMN2 | |
| SCHEMBL17200650 | 0.86 | MAPT (0.38) | MAPTKDM4EGALR3HTTSMN1; SMN2 | |
| SCHEMBL29367616 | 0.86 | MAPT (0.35) | MAPTKDM4EGALR3HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464056-B2 | Fungicidal 4-methylanilino pyrazoles | E I DU PONT DE NEMOURS AND COMPANY (US) | 2016-10-11 | — | — | US | claimed |
| EP-2864293-B1 | FUNGICIDAL 4-METHYLANILINO PYRAZOLES | DU PONT (US) | 2016-04-27 | — | — | EP | claimed |
| US-20150307456-A1 | FUNGICIDAL 4-METHYLANILINO PYRAZOLES | FMC CORPORATION | 2015-10-29 | — | — | US | claimed |
| US-9464056-B2 | Fungicidal 4-methylanilino pyrazoles | E I DU PONT DE NEMOURS AND COMPANY (US) | 2016-10-11 | — | — | US | disclosed |
| EP-2864293-B1 | FUNGICIDAL 4-METHYLANILINO PYRAZOLES | DU PONT (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20150307456-A1 | FUNGICIDAL 4-METHYLANILINO PYRAZOLES | FMC CORPORATION | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307456-A1 | FUNGICIDAL 4-METHYLANILINO PYRAZOLES | CYP2F1, CYP1B1, CYP4B1 | MAPT 4790/4885KDM4E 1163/4885GALR3 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.